Nexalin acquires PONM digital health platform for HALO Clarity for $1.3M in stock

Nexalin Technology, Inc.

Acquisition of all PONM shares for $1.3M in Nexalin common stock; first tranche of 959,016 shares issued at closing.
PONM platform, already deployed at UCSD, supports AI-integrated remote monitoring, EHR, and virtual-clinic workflows.
Planned 160-participant FDA pivotal trial for HALO Clarity in moderate-to-severe insomnia; enrollment expected Q2 2026.
GreenLight becomes a meaningful equity holder and enters strategic partnership for development, regulatory, and commercial support.
Collaboration Agreement with GLV provides ongoing development services at $10,000/month for 24-month initial term.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.